US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Telix Pharmaceuticals Ltd. (Uplisting)

13.05

-0.5400-3.97%

Post-market: 13.050.00000.00%16:10 EDT

Volume:55.38K

Turnover:722.36K

Market Cap:4.42B

PE:145.83

High:13.19

Open:13.19

Low:12.90

Close:13.59

Loading ...

Overview Company News Filings

Telix H1 2025 Results: Investor Webcast Notification

Telix Pharmaceuticals (ASX:TLX) Is Down 15.9% After Reaffirming 2025 Revenue Outlook and Increased R&D Spend

Simply Wall St.

UBS Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)

Bell Potter Keeps Their Buy Rating on Telix Pharmaceuticals (TLPPF)

Telix Pharmaceuticals to Release Shares from Voluntary Escrow

Telix Pharmaceuticals Receives SEC Subpoena for Prostate Cancer Treatment Disclosures

MT Newswires Live

Telix Pharmaceuticals Achieves 63% Revenue Growth in Q2 2025

Exploring Three High Growth Tech Stocks in Australia

Simply Wall St.

What Telix Pharmaceuticals (ASX:TLX)'s Gozellix HCPCS Code Approval Means For Shareholders

Simply Wall St.

Telix Pharmaceuticals Limited (ASX:TLX) most popular amongst individual investors who own 54% of the shares, institutions hold 28%

Simply Wall St.

Bell Potter Remains a Buy on Telix Pharmaceuticals (TLPPF)

Gozellix Receives Permanent HCPCS Code

Telix Pharmaceuticals’ Gozellix Secures Permanent HCPCS Code

Telix Pharmaceuticals Announces Cessation of Securities

Telix Pharmaceuticals Can Beat Annual Revenue Goal -- Market Talk

Boom! Doom! Zoom! | 3 July 2025: Virgin, Qantas, Telix, Promedicus and more

Telix Pharmaceuticals Initiated at Buy by HC Wainwright & Co.

Telix Pharmaceuticals Announces Quotation of New Securities on ASX

Telix Pharmaceuticals Updates Director’s Interest in Securities

Telix Pharmaceuticals (TLPPF) Receives a Buy from UBS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TLX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","market":"US","secType":"STK","nameCN":"Telix Pharmaceuticals Ltd. (Uplisting)","latestPrice":13.05,"timestamp":1754078400000,"preClose":13.59,"halted":0,"volume":55378,"hourTrading":{"tag":"盘后","latestPrice":13.05,"preClose":13.05,"latestTime":"16:10 EDT","volume":2,"amount":26.1,"timestamp":1754079004010},"delay":0,"floatShares":275410996,"shares":338382614,"eps":0.089486,"marketStatus":"Market Closed","change":-0.54,"latestTime":"08-01 16:00:00 EDT","open":13.19,"high":13.19,"low":12.899,"amount":722358.299574,"amplitude":0.021413,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.089486,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1754294400000},"marketStatusCode":7,"adr":0,"adrRate":1,"listingDate":1718337600000,"exchange":"NASDAQ","adjPreClose":13.59,"preHourTrading":{"tag":"盘前","latestPrice":13.13,"preClose":13.59,"latestTime":"08:00 EDT","volume":10,"amount":131.3,"timestamp":1754049601646},"postHourTrading":{"tag":"盘后","latestPrice":13.05,"preClose":13.05,"latestTime":"16:10 EDT","volume":2,"amount":26.1,"timestamp":1754079004010},"volumeRatio":0.9116080301551297},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","floatShares":275410996,"roa":"5.33%","roe":"13.92%","lyrEps":0.093266,"volumeRatio":0.9116080301551297,"shares":338382614,"dividePrice":0,"high":13.19,"amplitude":0.021413,"preClose":13.59,"low":12.899,"week52Low":12.899,"pbRate":"12.02","psRate":"8.72","week52High":30.36,"institutionHeld":0,"latestPrice":13.05,"eps":0.089486,"divideRate":0,"volume":55378,"delay":0,"ttmEps":0.089486,"open":13.19,"prevYearClose":15.4,"prevWeekClose":14.2,"prevMonthClose":13.59,"prevQuarterClose":16.07,"fiveDayClose":14.2,"twentyDayClose":16.07,"sixtyDayClose":18.28,"earningDate":1755705600000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2555621290","title":"Telix H1 2025 Results: Investor Webcast Notification","url":"https://stock-news.laohu8.com/highlight/detail?id=2555621290","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555621290?lang=en_us&edition=fundamental","pubTime":"2025-07-30 06:58","pubTimestamp":1753829880,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, July  30, 2025  (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will release its financial results for t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/29/3123694/0/en/Telix-H1-2025-Results-Investor-Webcast-Notification.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4141","BK4543","ASX","BK4526","BK4139","TLX"],"gpt_icon":0},{"id":"2554471133","title":"Telix Pharmaceuticals (ASX:TLX) Is Down 15.9% After Reaffirming 2025 Revenue Outlook and Increased R&D Spend","url":"https://stock-news.laohu8.com/highlight/detail?id=2554471133","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554471133?lang=en_us&edition=fundamental","pubTime":"2025-07-26 20:13","pubTimestamp":1753532024,"startTime":"0","endTime":"0","summary":"On July 22, 2025, Telix Pharmaceuticals confirmed its revenue guidance for fiscal year 2025 at A$770 million to A$800 million, driven by ongoing Illuccix sales and 11 months of contributions from its RLS acquisition, while also projecting a 20% to 25% increase in R&D expenditures over the previous year.\nThis reaffirmed outlook highlights Telix's focus on balancing robust commercial operations with sizable investment in future research initiatives.\nWe’ll explore how Telix’s increased R&D...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-is-down-159-after-reaffirming-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX.AU","TLX"],"gpt_icon":0},{"id":"2553951072","title":"UBS Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2553951072","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553951072?lang=en_us&edition=fundamental","pubTime":"2025-07-23 12:05","pubTimestamp":1753243517,"startTime":"0","endTime":"0","summary":"In a report released today, David Dai from UBS maintained a Buy rating on Telix Pharmaceuticals, with a price target of A$36.00. The company’s shar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ubs-sticks-to-its-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ubs-sticks-to-its-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","TLPPF"],"gpt_icon":0},{"id":"2553649082","title":"Bell Potter Keeps Their Buy Rating on Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2553649082","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553649082?lang=en_us&edition=fundamental","pubTime":"2025-07-23 08:35","pubTimestamp":1753230931,"startTime":"0","endTime":"0","summary":"Bell Potter analyst John Hester maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$34.00. The company’s shares clos...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bell-potter-keeps-their-buy-rating-on-telix-pharmaceuticals-tlppf-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bell-potter-keeps-their-buy-rating-on-telix-pharmaceuticals-tlppf-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","TLPPF"],"gpt_icon":0},{"id":"2553826139","title":"Telix Pharmaceuticals to Release Shares from Voluntary Escrow","url":"https://stock-news.laohu8.com/highlight/detail?id=2553826139","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553826139?lang=en_us&edition=fundamental","pubTime":"2025-07-23 07:39","pubTimestamp":1753227574,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals ( ($AU:TLX) ) has issued an announcement. Telix Pharmaceuticals announced the release of 47,256 ordinary shares from voluntar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-to-release-shares-from-voluntary-escrow-6?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-to-release-shares-from-voluntary-escrow-6?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX"],"gpt_icon":0},{"id":"2553198252","title":"Telix Pharmaceuticals Receives SEC Subpoena for Prostate Cancer Treatment Disclosures","url":"https://stock-news.laohu8.com/highlight/detail?id=2553198252","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553198252?lang=en_us&edition=fundamental","pubTime":"2025-07-22 23:31","pubTimestamp":1753198273,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said Tuesday that it received a subpoena from the US Securities and Exchange Commission asking for documents and information related to disclosures regarding the development of the company's prostate cancer treatments.The company said it is fully cooperating with the SEC and is in the process of responding to the information request.Telix also said it decided to notify the Australian Securities and Investments Commission of the SEC's request.Price: 16.67, Change: +0.07, Percent Change: +0.42","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","BK7067","TLX","BK4139"],"gpt_icon":0},{"id":"2553282723","title":"Telix Pharmaceuticals Achieves 63% Revenue Growth in Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2553282723","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553282723?lang=en_us&edition=fundamental","pubTime":"2025-07-22 14:42","pubTimestamp":1753166569,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Telix Pharmaceuticals ( ($AU:TLX) ). Telix Pharmaceuticals reported a significant 63% year-over-year increase i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-achieves-63-revenue-growth-in-q2-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-achieves-63-revenue-growth-in-q2-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX"],"gpt_icon":0},{"id":"2553070724","title":"Exploring Three High Growth Tech Stocks in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2553070724","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553070724?lang=en_us&edition=fundamental","pubTime":"2025-07-22 03:05","pubTimestamp":1753124748,"startTime":"0","endTime":"0","summary":"As we reach the end of the first day of Week 30 in 2025, the Australian market experienced a pullback with the ASX dipping back to the high 8,600s after an unexpected climb into the 8,700s on Friday. Despite this minor setback and profit-taking activities following Wall Street's flat finish last week, investor sentiment remains cautiously optimistic with US futures trending upward and no immediate adverse impacts from recent tariffs. In this context, identifying high-growth tech stocks in...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-pme/pro-medicus-shares/news/exploring-three-high-growth-tech-stocks-in-australia-12","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX.AU","BK7067","XKO.AU","XJO.AU","BK7002","BK7094","PME.AU","SEK.AU","XAO.AU","TLX","BK4139"],"gpt_icon":0},{"id":"2552148484","title":"What Telix Pharmaceuticals (ASX:TLX)'s Gozellix HCPCS Code Approval Means For Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2552148484","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552148484?lang=en_us&edition=fundamental","pubTime":"2025-07-19 17:30","pubTimestamp":1752917456,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals announced that its next-generation PSMA PET imaging agent, Gozellix, has been granted a permanent Healthcare Common Procedure Coding System (HCPCS) code by the U.S. Centers for Medicare & Medicaid Services, effective from October 1, 2025.\nThis approval marks a pivotal development that could streamline provider reimbursement and potentially increase accessibility to advanced prostate cancer imaging.\nWe'll explore how expanded reimbursement options could impact Telix...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/what-telix-pharmaceuticals-asxtlxs-gozellix-hcpcs-code-appro","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","TLX.AU","TLX","BK7067"],"gpt_icon":0},{"id":"2551253136","title":"Telix Pharmaceuticals Limited (ASX:TLX) most popular amongst individual investors who own 54% of the shares, institutions hold 28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551253136","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551253136?lang=en_us&edition=fundamental","pubTime":"2025-07-15 04:58","pubTimestamp":1752526689,"startTime":"0","endTime":"0","summary":"Key Insights Telix Pharmaceuticals' significant individual investors ownership suggests that the key decisions are...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-limited-asxtlx-most-popular-amongst-in","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","TLX","TLX.AU","BK4139"],"gpt_icon":0},{"id":"2550672361","title":"Bell Potter Remains a Buy on Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2550672361","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550672361?lang=en_us&edition=fundamental","pubTime":"2025-07-11 07:35","pubTimestamp":1752190523,"startTime":"0","endTime":"0","summary":"Bell Potter analyst John Hester maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$34.00. The company’s shares clos...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bell-potter-remains-a-buy-on-telix-pharmaceuticals-tlppf-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bell-potter-remains-a-buy-on-telix-pharmaceuticals-tlppf-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLPPF","BK4139","TLX"],"gpt_icon":0},{"id":"2550669646","title":"Gozellix Receives Permanent HCPCS Code","url":"https://stock-news.laohu8.com/highlight/detail?id=2550669646","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550669646?lang=en_us&edition=fundamental","pubTime":"2025-07-10 06:45","pubTimestamp":1752101100,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, July  10, 2025  (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that its next-generation PSMA1 PET2 imaging ag","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/09/3112948/0/en/Gozellix-Receives-Permanent-HCPCS-Code.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0949170772.SGD","BK4526","LU1894683348.USD","LU0553294199.USD","LU0738911758.USD","LU2637428348.USD","BK4165","BK4588","LU1894683264.USD","BK4543","CMS","BK4141","ASX","BK4585","LU1003077747.HKD","BK4533","BK4139","BK4084","BK4208","LU2500361329.USD","ADT","LU0545039389.USD","PSA","BCR","BK4192","LU0661504455.SGD","BK4217","TLX","LU2346227817.USD"],"gpt_icon":0},{"id":"2550503846","title":"Telix Pharmaceuticals’ Gozellix Secures Permanent HCPCS Code","url":"https://stock-news.laohu8.com/highlight/detail?id=2550503846","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550503846?lang=en_us&edition=fundamental","pubTime":"2025-07-09 09:52","pubTimestamp":1752025953,"startTime":"0","endTime":"0","summary":"The latest update is out from Telix Pharmaceuticals ( ($AU:TLX) ). Telix Pharmaceuticals announced that its next-generation PSMA PET imaging agent,...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-gozellix-secures-permanent-hcpcs-code?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-gozellix-secures-permanent-hcpcs-code?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX"],"gpt_icon":0},{"id":"2550627576","title":"Telix Pharmaceuticals Announces Cessation of Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2550627576","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550627576?lang=en_us&edition=fundamental","pubTime":"2025-07-09 06:12","pubTimestamp":1752012734,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals ( ($AU:TLX) ) has shared an announcement. Telix Pharmaceuticals Limited announced the cessation of certain securities, specif...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-announces-cessation-of-securities-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-announces-cessation-of-securities-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX"],"gpt_icon":0},{"id":"2549736379","title":"Telix Pharmaceuticals Can Beat Annual Revenue Goal -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2549736379","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549736379?lang=en_us&edition=fundamental","pubTime":"2025-07-07 06:21","pubTimestamp":1751840460,"startTime":"0","endTime":"0","summary":"2221 GMT - Jefferies expects Telix Pharmaceuticals to beat FY 2025 revenue guidance, partly because it will benefit from sales of prostate cancer imaging investigational product Illuccix in some EU and Latin American countries. Analyst David Stanton says his annual revenue forecast is 4% above the top end of Telix's stated target. This is because Telix didn't include revenue from Illuccix in EU jurisdictions with no marketing authorization at that time. However, Norway, Luxembourg and Brazil issued marketing approval for Illuccix in 1Q of FY 2025. \"Assuming a six-month process to receive reimbursement approval and the start of sales, we believe Telix will receive revenue from these areas in 4Q of FY 2025,\" Jefferies says. \"We forecast this revenue contribution at A$24 million in FY 2025.\" ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","TLX"],"gpt_icon":0},{"id":"2548387173","title":"Boom! Doom! Zoom! | 3 July 2025: Virgin, Qantas, Telix, Promedicus and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2548387173","media":"Switzer","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548387173?lang=en_us&edition=fundamental","pubTime":"2025-07-04 06:30","pubTimestamp":1751581814,"startTime":"0","endTime":"0","summary":"It's a weird one out there right now. As the resume of Trump tariffs looms large over the market, Peter Switzer and Paul Rickard look at everything from Telix (TLX) to ProMedicus (PME), Virgin (VGN) to Qantas (QAN), and explain why your ETFs and trusts might look a little weird right now on the charts.","market":"hk","thumbnail":"https://switzer.com.au/wp-content/uploads/BDZ-Splash-Background-Blue.jpg","type":0,"news_type":0,"thumbnails":["https://switzer.com.au/wp-content/uploads/BDZ-Splash-Background-Blue.jpg"],"rights":{"source":"switzer_stock","url":"https://switzer.com.au/the-experts/switzer-tv/boom-doom-zoom-3-july-2025-virgin-qantas-telix-promedicus-and-more/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://switzer.com.au/the-experts/switzer-tv/boom-doom-zoom-3-july-2025-virgin-qantas-telix-promedicus-and-more/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"switzer_stock","symbols":["BK4528","BK4548","BK7030","BK4613","BK4588","BK7067","BK4139","ZM","TLX.AU","BK4212","BK4585","VGN.AU","BK4532","BK4023","BK4554","BK4535","BK7094","BK4505","PME.AU","LU1861558580.USD","BK4525","QAN.AU","LU1861559042.SGD","BK4551","TLX","PME"],"gpt_icon":0},{"id":"2548806551","title":"Telix Pharmaceuticals Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2548806551","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548806551?lang=en_us&edition=fundamental","pubTime":"2025-07-03 19:04","pubTimestamp":1751540640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TLX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 03, 2025 07:04 ET (11:04 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX","BK4139"],"gpt_icon":0},{"id":"2544191191","title":"Telix Pharmaceuticals Announces Quotation of New Securities on ASX","url":"https://stock-news.laohu8.com/highlight/detail?id=2544191191","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544191191?lang=en_us&edition=fundamental","pubTime":"2025-06-20 06:38","pubTimestamp":1750372691,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals ( ($AU:TLX) ) has provided an announcement. Telix Pharmaceuticals Limited has announced the quotation of 133,825 ordinary ful...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-announces-quotation-of-new-securities-on-asx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-announces-quotation-of-new-securities-on-asx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4139"],"gpt_icon":0},{"id":"2544279916","title":"Telix Pharmaceuticals Updates Director’s Interest in Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2544279916","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544279916?lang=en_us&edition=fundamental","pubTime":"2025-06-18 07:10","pubTimestamp":1750201804,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals ( ($AU:TLX) ) has shared an update. Telix Pharmaceuticals has announced a change in the director’s interest, specifically for...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-updates-directors-interest-in-securities?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-updates-directors-interest-in-securities?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4139"],"gpt_icon":0},{"id":"2543521477","title":"Telix Pharmaceuticals (TLPPF) Receives a Buy from UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2543521477","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543521477?lang=en_us&edition=fundamental","pubTime":"2025-06-13 09:05","pubTimestamp":1749776713,"startTime":"0","endTime":"0","summary":"UBS analyst David Dai maintained a Buy rating on Telix Pharmaceuticals (TLPPF – Research Report) today and set a price target of A$36.00. The compa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/telix-pharmaceuticals-tlppf-receives-a-buy-from-ubs-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/telix-pharmaceuticals-tlppf-receives-a-buy-from-ubs-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4139","TLPPF"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":106,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX\",params:#limit:5,,,undefined,":[{"date":"2025-08-21","symbol":"TLX","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755763200000,"name":null,"time":"","dateTimestamp":1755748800000,"actualEps":null},{"market":"US","date":"2025-02-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740027600000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TLX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1751601600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TLX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TLX","date":"2025-08-01","current":136.589468,"percent":0,"low":136.589468,"twenty":164.955304,"median":173.25664,"eighty":185.381192,"high":205.576265,"avg":174.47501,"sd":13.844777,"marketCap":4384547406.6},"quantilePoints":[{"date":"2024-11-15","current":155.824924,"twenty":155.852142,"median":155.89297,"eighty":156.178762,"marketCap":4970652360.72},{"date":"2024-11-22","current":153.647458,"twenty":154.191824,"median":155.858947,"eighty":156.314854,"marketCap":4920980791.17},{"date":"2024-11-29","current":168.345354,"twenty":154.8995,"median":156.063085,"eighty":158.49232,"marketCap":5381208976.41},{"date":"2024-12-06","current":169.502133,"twenty":155.171684,"median":156.641474,"eighty":168.045953,"marketCap":5368295184.8},{"date":"2024-12-13","current":166.916392,"twenty":155.838533,"median":162.3233,"eighty":168.045953,"marketCap":5240175366.69},{"date":"2024-12-20","current":168.345354,"twenty":155.961016,"median":166.508117,"eighty":168.916939,"marketCap":5183140063.85},{"date":"2024-12-27","current":169.774316,"twenty":156.233199,"median":167.052484,"eighty":169.706271,"marketCap":5196235069.7},{"date":"2025-01-03","current":162.241165,"twenty":156.342072,"median":167.052484,"eighty":169.542961,"marketCap":4949346723.31},{"date":"2025-01-10","current":163.261978,"twenty":156.5326,"median":167.392713,"eighty":169.228803,"marketCap":4970930045.19},{"date":"2025-01-17","current":180.956065,"twenty":158.029608,"median":167.50507,"eighty":169.864326,"marketCap":5535715919.89},{"date":"2025-01-24","current":187.353158,"twenty":159.608271,"median":167.889662,"eighty":170.577257,"marketCap":5785750657.37},{"date":"2025-01-31","current":199.670965,"twenty":161.249345,"median":168.229933,"eighty":175.407845,"marketCap":6122321793.53},{"date":"2025-02-07","current":198.349538,"twenty":162.241165,"median":168.549491,"eighty":182.861582,"marketCap":6131109878.71},{"date":"2025-02-14","current":185.473256,"twenty":162.64949,"median":169.046583,"eighty":187.353158,"marketCap":5747906307.1},{"date":"2025-02-21","current":203.261161,"twenty":163.302811,"median":169.706271,"eighty":187.353158,"marketCap":6486347833.54},{"date":"2025-02-28","current":187.883767,"twenty":163.584606,"median":170.12499,"eighty":192.087093,"marketCap":5864055113.17},{"date":"2025-03-07","current":182.602424,"twenty":164.112905,"median":170.795004,"eighty":190.960114,"marketCap":5800401146.04},{"date":"2025-03-14","current":179.829719,"twenty":164.766144,"median":174.911776,"eighty":189.692293,"marketCap":5647282174.13},{"date":"2025-03-21","current":184.714961,"twenty":166.589772,"median":175.670662,"eighty":188.147066,"marketCap":5803981960.09},{"date":"2025-03-28","current":187.327482,"twenty":166.94361,"median":178.971501,"eighty":190.960114,"marketCap":5900183330.18},{"date":"2025-04-04","current":159.860903,"twenty":166.94361,"median":178.262158,"eighty":189.692293,"marketCap":5073492527.81},{"date":"2025-04-11","current":177.179731,"twenty":166.589772,"median":177.679515,"eighty":188.147066,"marketCap":5496976372.28},{"date":"2025-04-17","current":173.797147,"twenty":166.916392,"median":177.619467,"eighty":187.883767,"marketCap":5535140863.85},{"date":"2025-04-25","current":193.309359,"twenty":167.052484,"median":178.059203,"eighty":190.062144,"marketCap":6172717887.8},{"date":"2025-05-02","current":198.453445,"twenty":167.392713,"median":178.295984,"eighty":190.062144,"marketCap":6327668326.52},{"date":"2025-05-09","current":181.396737,"twenty":167.481337,"median":179.235568,"eighty":190.062144,"marketCap":5809793224.05},{"date":"2025-05-16","current":176.029393,"twenty":167.481337,"median":178.295984,"eighty":189.78972,"marketCap":5619140101.04},{"date":"2025-05-23","current":172.647682,"twenty":167.528804,"median":178.059203,"eighty":189.451294,"marketCap":5528513460.13},{"date":"2025-05-30","current":176.779306,"twenty":167.780801,"median":177.456621,"eighty":188.460572,"marketCap":5687082652.57},{"date":"2025-06-06","current":173.121803,"twenty":167.88049,"median":177.318176,"eighty":187.949592,"marketCap":5638091901.1},{"date":"2025-06-13","current":167.838743,"twenty":167.88049,"median":176.508379,"eighty":187.45928,"marketCap":5463186103.94},{"date":"2025-06-20","current":168.923551,"twenty":167.889662,"median":176.029393,"eighty":187.353158,"marketCap":5442074695.06},{"date":"2025-06-27","current":165.669807,"twenty":167.592888,"median":175.625224,"eighty":187.337752,"marketCap":5412704421.76},{"date":"2025-07-03","current":162.348276,"twenty":167.428163,"median":175.082406,"eighty":187.024133,"marketCap":5325445922.59},{"date":"2025-07-11","current":163.297285,"twenty":166.671427,"median":174.480785,"eighty":186.439488,"marketCap":5350247552.51},{"date":"2025-07-18","current":171.228286,"twenty":165.90028,"median":173.909122,"eighty":186.045921,"marketCap":5541358073.91},{"date":"2025-07-25","current":144.045965,"twenty":165.670181,"median":173.731386,"eighty":185.637634,"marketCap":4750367012.62},{"date":"2025-08-01","current":136.589468,"twenty":164.955304,"median":173.25664,"eighty":185.381192,"marketCap":4384547406.6}],"updateTime":1754166604077}}}